Orphanin FQ/nociceptin-mediated desensitization of opioid receptor-like 1 receptor and mu opioid receptors involves protein kinase C: a molecular mechanism for heterologous cross-talk.
Morphine tolerance in vivo is reduced following blockade of the orphanin FQ/nociceptin (OFQ/N)/opioid receptor-like 1 (ORL1) receptor system, suggesting that OFQ/N contributes to the development of morphine tolerance. We previously reported that a 60-min activation of ORL1 receptors natively expressed in BE(2)-C cells desensitized both mu and ORL1 receptor-mediated inhibition of cAMP. Investigating the mechanism(s) of OFQ/N-mediated mu and ORL1 receptor cross-talk, we found that pretreatment with the protein kinase C inhibitor, chelerythrine chloride (1 microM), blocked OFQ/N-mediated homologous desensitization of ORL1 and heterologous desensitization of mu opioid receptors. Furthermore, depletion of PKC by 12-O-tetradecanoylphorbol-13-acetate exposure (48 h, 1 microM) also prevented OFQ/N-mediated mu and ORL1 desensitization. OFQ/N pretreatment resulted in translocation of PKC-alpha, G protein-coupled receptor kinase 2 (GRK2) and GRK3 from the cytosol to the membrane, and this translocation was also blocked by chelerythrine. Reduction of GRK2 and GRK3 levels by antisense, but not sense DNA treatment blocks ORL1 and mu receptor desensitization. This suggests that PKC-alpha is required for GRK2 and GRK3 translocation to the membrane, where GRK can inactivate ORL1 and mu opioid receptors upon rechallenge with the appropriate agonist. Our results demonstrate for the first time the involvement of conventional PKC isozymes in OFQ/N-induced mu-ORL1 cross-talk, and represent a possible mechanism for OFQ/N-induced anti-opioid actions.
Mandyam
Chitra D
CD
Department of Pharmacological and Pharmaceutical Sciences, 521 Building Science and Research 2, University of Houston, Houston, TX 77204-5037, USA.
Thakker
Deepak R
DR
Christensen
Jennifer L
JL
Standifer
Kelly M
KM
D000470:Alkaloids; D053119:Benzophenanthridines; D002462:Cell Membrane / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism; D017868:Cyclic AMP-Dependent Protein Kinases / Q000235:genetics; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / Q000493:pharmacokinetics / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D054770:G-Protein-Coupled Receptor Kinase 3; D006801:Humans; D009447:Neuroblastoma; D020319:Oligodeoxyribonucleotides, Antisense / Q000494:pharmacology; D018847:Opioid Peptides / Q000494:pharmacology*; D010617:Phenanthridines / Q000494:pharmacology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D017346:Protein Serine-Threonine Kinases / Q000235:genetics; D020239:Receptor Cross-Talk / Q000502:physiology; D011957:Receptors, Opioid / Q000187:drug effects / Q000502:physiology*; D017450:Receptors, Opioid, mu / Q000187:drug effects / Q000502:physiology*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D051552:beta-Adrenergic Receptor Kinases; D000094942:Nociceptin Receptor; D000097629:Nociceptin
D000470:Alkaloids; D053119:Benzophenanthridines; D000242:Cyclic AMP; D017868:Cyclic AMP-Dependent Protein Kinases; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D004791:Enzyme Inhibitors; D054770:G-Protein-Coupled Receptor Kinase 3; D020319:Oligodeoxyribonucleotides, Antisense; D018847:Opioid Peptides; D010617:Phenanthridines; D011493:Protein Kinase C; D017346:Protein Serine-Threonine Kinases; D011957:Receptors, Opioid; D017450:Receptors, Opioid, mu; D013755:Tetradecanoylphorbol Acetate; D051552:beta-Adrenergic Receptor Kinases; D000094942:Nociceptin Receptor; D000097629:Nociceptin; C016299:chelerythrine; C517848:GRK3 protein, human; C000722283:OPRL1 protein, human